民国卫士财神的个人主页 - 老虎社区

民国卫士财神

民国卫士财神

暂无个人介绍

IP属地：0

106关注

2粉丝

2主题

0勋章

民国卫士财神

2020-02-28

$Portola Pharmaceuticals Inc.(PTLA)$先买个底仓，后面再加；

民国卫士财神

2020-02-28

$Portola Pharmaceuticals Inc.(PTLA)$买入1000股底仓，后面再加，准备放个几年

民国卫士财神

2020-02-28

厉害

抱歉，原内容已删除

民国卫士财神

2020-10-30

好像是400多万股

Bellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market

民国卫士财神

2021-02-17

就是割韭菜的忽悠，估计公司正准备增发股票割韭菜泡汤了

美股异动 | 亿航智能(EH.US)盘前转跌逾15% 成交额已超1亿

民国卫士财神

2021-02-06

管理层吃老本，要不了多久就被被淘汰掉，看吧

民国卫士财神

2021-02-06

一个10年350倍回报的公司，太励志了，保存一下

民国卫士财神

2021-02-05

好讨厌的一个品牌，到处刷存在，核心技术全部拿来主义，一个不专注品质的公司，是不值得投资的

小米发布四曲瀑布屏概念机，四周边框全部消失

民国卫士财神

2020-10-30

增发股票了吗？

Bellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market

民国卫士财神

2020-04-03

呵呵，有神马用

抱歉，原内容已删除

民国卫士财神

2020-02-28

$Portola Pharmaceuticals Inc.(PTLA)$我来建个仓，产品非常好；市场空间巨大，现在公司管理和销售出了问题。

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3519516576436036","uuid":"3519516576436036","gmtCreate":1556424907105,"gmtModify":1612615289626,"name":"民国卫士财神","pinyin":"mgwscsminguoweishicaishen","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/d777c08923786c9a2d938a63d5edd6e1","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":106,"tweetSize":11,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":2,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":59,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.19","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.71%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"02aa7f16703b4ce4ace6f1a7665789cc-1","templateUuid":"02aa7f16703b4ce4ace6f1a7665789cc","name":"知识体验官","description":"观看学堂课程满5节","bigImgUrl":"https://static.tigerbbs.com/fb5ae275631fb96a92d475cdc85d2302","smallImgUrl":"https://static.tigerbbs.com/c2660a1935bd2105e97c9915619936c3","grayImgUrl":null,"redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.05","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":2006},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.30","exceedPercentage":"80.43%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":6,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"0","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":385554793,"gmtCreate":1613567195512,"gmtModify":1613567195512,"author":{"id":"3519516576436036","authorId":"3519516576436036","name":"民国卫士财神","avatar":"https://static.tigerbbs.com/d777c08923786c9a2d938a63d5edd6e1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3519516576436036","authorIdStr":"3519516576436036"},"themes":[],"htmlText":"就是割韭菜的忽悠，估计公司正准备增发股票割韭菜泡汤了","listText":"就是割韭菜的忽悠，估计公司正准备增发股票割韭菜泡汤了","text":"就是割韭菜的忽悠，估计公司正准备增发股票割韭菜泡汤了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/385554793","repostId":"2112710837","repostType":2,"repost":{"id":"2112710837","kind":"news","pubTimestamp":1613565105,"share":"https://www.laohu8.com/m/news/2112710837?lang=&edition=full","pubTime":"2021-02-17 20:31","market":"hk","language":"zh","title":"美股异动 | 亿航智能(EH.US)盘前转跌逾15% 成交额已超1亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2112710837","media":"智通财经","summary":"智通财经APP获悉，亿航智能(EH.US)盘前交投活跃，股价涨超34%后转跌逾15%，成交额已超1亿。截止发稿，跌9.05%，报42.11美元，成交额1.03亿美元。消息面上，针对Wolfpack  Research于2021年2月16日发布的一份报告中提出的指控，亿航智能发布声明称，公司坚信报告中包含大量错误、未经证实的陈述和对信息的误读。公司将考虑采取任何必要和适当的行动来保护公司及其所有股东的利益。亿航智能致力于保持最高标准的公司治理，并按照美国证券交易委员会和纳斯达克股票市场的适用规则和法规进行透明和及时的披露。","content":"<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/EH\">亿航智能</a>(EH.US)盘前交投活跃，股价涨超34%后转跌逾15%，成交额已超1亿。截止发稿，跌9.05%，报42.11美元，成交额1.03亿美元。</p><p>消息面上，针对Wolfpack  Research于2021年2月16日发布的一份报告中提出的指控，亿航智能发布声明称，公司坚信报告中包含大量错误、未经证实的陈述和对信息的误读。公司将考虑采取任何必要和适当的行动来保护公司及其所有股东的利益。亿航智能致力于保持最高标准的公司治理，并按照美国证券交易委员会和纳斯达克股票市场的适用规则和法规进行透明和及时的披露。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美股异动 | 亿航智能(EH.US)盘前转跌逾15% 成交额已超1亿</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美股异动 | 亿航智能(EH.US)盘前转跌逾15% 成交额已超1亿\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-17 20:31 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/412490.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，亿航智能(EH.US)盘前交投活跃，股价涨超34%后转跌逾15%，成交额已超1亿。截止发稿，跌9.05%，报42.11美元，成交额1.03亿美元。消息面上，针对Wolfpack  Research于2021年2月16日发布的一份报告中提出的指控，亿航智能发布声明称，公司坚信报告中包含大量错误、未经证实的陈述和对信息的误读。公司将考虑采取任何必要和适当的行动来保护公司及其所有股东...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/412490.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750","relate_stocks":{"EH":"亿航智能"},"source_url":"http://www.zhitongcaijing.com/content/detail/412490.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2112710837","content_text":"智通财经APP获悉，亿航智能(EH.US)盘前交投活跃，股价涨超34%后转跌逾15%，成交额已超1亿。截止发稿，跌9.05%，报42.11美元，成交额1.03亿美元。消息面上，针对Wolfpack  Research于2021年2月16日发布的一份报告中提出的指控，亿航智能发布声明称，公司坚信报告中包含大量错误、未经证实的陈述和对信息的误读。公司将考虑采取任何必要和适当的行动来保护公司及其所有股东的利益。亿航智能致力于保持最高标准的公司治理，并按照美国证券交易委员会和纳斯达克股票市场的适用规则和法规进行透明和及时的披露。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1487,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":380748026,"gmtCreate":1612602193265,"gmtModify":1703763950438,"author":{"id":"3519516576436036","authorId":"3519516576436036","name":"民国卫士财神","avatar":"https://static.tigerbbs.com/d777c08923786c9a2d938a63d5edd6e1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3519516576436036","authorIdStr":"3519516576436036"},"themes":[],"htmlText":"管理层吃老本，要不了多久就被被淘汰掉，看吧","listText":"管理层吃老本，要不了多久就被被淘汰掉，看吧","text":"管理层吃老本，要不了多久就被被淘汰掉，看吧","images":[{"img":"https://static.tigerbbs.com/b0e3ec13953a98a2a7ad61c45ec8f2ee","width":"1176","height":"2860"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/380748026","isVote":1,"tweetType":1,"viewCount":2902,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":380741601,"gmtCreate":1612602043103,"gmtModify":1703763949920,"author":{"id":"3519516576436036","authorId":"3519516576436036","name":"民国卫士财神","avatar":"https://static.tigerbbs.com/d777c08923786c9a2d938a63d5edd6e1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3519516576436036","authorIdStr":"3519516576436036"},"themes":[],"htmlText":"一个10年350倍回报的公司，太励志了，保存一下","listText":"一个10年350倍回报的公司，太励志了，保存一下","text":"一个10年350倍回报的公司，太励志了，保存一下","images":[{"img":"https://static.tigerbbs.com/17f1154c260ba3beffd6d70db6e71c7c","width":"1176","height":"2959"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/380741601","isVote":1,"tweetType":1,"viewCount":3278,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":380304195,"gmtCreate":1612512034017,"gmtModify":1703762892228,"author":{"id":"3519516576436036","authorId":"3519516576436036","name":"民国卫士财神","avatar":"https://static.tigerbbs.com/d777c08923786c9a2d938a63d5edd6e1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3519516576436036","authorIdStr":"3519516576436036"},"themes":[],"htmlText":"好讨厌的一个品牌，到处刷存在，核心技术全部拿来主义，一个不专注品质的公司，是不值得投资的","listText":"好讨厌的一个品牌，到处刷存在，核心技术全部拿来主义，一个不专注品质的公司，是不值得投资的","text":"好讨厌的一个品牌，到处刷存在，核心技术全部拿来主义，一个不专注品质的公司，是不值得投资的","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/380304195","repostId":"2109729194","repostType":2,"repost":{"id":"2109729194","kind":"news","pubTimestamp":1612509420,"share":"https://www.laohu8.com/m/news/2109729194?lang=&edition=full","pubTime":"2021-02-05 15:17","market":"hk","language":"zh","title":"小米发布四曲瀑布屏概念机，四周边框全部消失","url":"https://stock-news.laohu8.com/highlight/detail?id=2109729194","media":"界面新闻","summary":"同时，小米四曲瀑布屏概念机采用了无孔设计，目前手机已有的实体按键与所有开孔全部消失，充电方式为大功率无线充电。小米四曲瀑布屏概念机取消了实体键，那么如何解决音量键也是这款产品的看点之一。值得一提的是，2019年9月，小米曾发布过MIX Alpha环绕屏概念手机，但由于工艺难题最终放弃量产。因此，目前小米四曲瀑布屏概念机并未公布售价，也未宣布是否会正式量产。","content":"<div>\n<p>记者｜王公逸2月5日，小米四曲瀑布屏概念机正式亮相。此款概念机四面为88°超曲边框，从官方释出的视频以及图片中基本可知，从正面观看很难看到手机的四面边框，实现了真正的“视觉无边框”。同时，小米四曲瀑布屏概念机采用了无孔设计，目前手机已有的实体按键与所有开孔全部消失，充电方式为大功率无线充电。同时为了保留前置镜头，新机应该会采用屏下摄像头的方案。此外，该款产品也通过柔性薄膜屏幕发声技术，以此来替代...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202102051518017a47c40f&s=b\">Web Link</a>\n\n</div>\n","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>小米发布四曲瀑布屏概念机，四周边框全部消失</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n小米发布四曲瀑布屏概念机，四周边框全部消失\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-05 15:17 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202102051518017a47c40f&s=b><strong>界面新闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>记者｜王公逸2月5日，小米四曲瀑布屏概念机正式亮相。此款概念机四面为88°超曲边框，从官方释出的视频以及图片中基本可知，从正面观看很难看到手机的四面边框，实现了真正的“视觉无边框”。同时，小米四曲瀑布屏概念机采用了无孔设计，目前手机已有的实体按键与所有开孔全部消失，充电方式为大功率无线充电。同时为了保留前置镜头，新机应该会采用屏下摄像头的方案。此外，该款产品也通过柔性薄膜屏幕发声技术，以此来替代...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202102051518017a47c40f&s=b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/3df686d3a6ca977e8c6841905eb7e18c","relate_stocks":{"01810":"小米集团-W"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202102051518017a47c40f&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2109729194","content_text":"记者｜王公逸2月5日，小米四曲瀑布屏概念机正式亮相。此款概念机四面为88°超曲边框，从官方释出的视频以及图片中基本可知，从正面观看很难看到手机的四面边框，实现了真正的“视觉无边框”。同时，小米四曲瀑布屏概念机采用了无孔设计，目前手机已有的实体按键与所有开孔全部消失，充电方式为大功率无线充电。同时为了保留前置镜头，新机应该会采用屏下摄像头的方案。此外，该款产品也通过柔性薄膜屏幕发声技术，以此来替代智能手机上的传统听筒。小米四曲瀑布屏概念机取消了实体键，那么如何解决音量键也是这款产品的看点之一。此前，作为替代音量键的方案，华为曾采用了双敲侧边呼出的设计，而vivo也推出过压感振动的解决方案。雷军此前曾在微博透露，小米未来可能发布一款万元高端手机，外界猜测可能是小米的折叠屏新机，但目前来看，也可能会是这款四曲瀑布屏概念机。值得一提的是，2019年9月，小米曾发布过MIX Alpha环绕屏概念手机，但由于工艺难题最终放弃量产。因此，目前小米四曲瀑布屏概念机并未公布售价，也未宣布是否会正式量产。","news_type":1},"isVote":1,"tweetType":1,"viewCount":2697,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":308471888,"gmtCreate":1604062629544,"gmtModify":1703831895477,"author":{"id":"3519516576436036","authorId":"3519516576436036","name":"民国卫士财神","avatar":"https://static.tigerbbs.com/d777c08923786c9a2d938a63d5edd6e1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3519516576436036","authorIdStr":"3519516576436036"},"themes":[],"htmlText":"好像是400多万股","listText":"好像是400多万股","text":"好像是400多万股","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/308471888","repostId":"2079414686","repostType":2,"repost":{"id":"2079414686","kind":"news","pubTimestamp":1604006160,"share":"https://www.laohu8.com/m/news/2079414686?lang=&edition=full","pubTime":"2020-10-30 05:16","market":"us","language":"en","title":"Bellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2079414686","media":"GlobeNewswire","summary":"HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in","content":"<html><body><p>HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/BLCM\">Bellicum Pharmaceuticals, Inc.</a> (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the pricing of an underwritten offering priced at-the-market under Nasdaq rules of 4,149,378 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase up to 4,149,378 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with <a href=\"https://laohu8.com/S/AONE\">one</a> warrant to purchase <a href=\"https://laohu8.com/S/AONE.U\">one</a> share of common stock at a combined effective price of $6.025. The offering is expected to involve a limited number of healthcare-dedicated institutional investors, including significant participation from two of Bellicum’s existing healthcare-dedicated institutional investors.<br/></p>\n<p>H.C. Wainwright &amp; Co. is acting as sole book-running manager for the offering.</p>\n<p>The gross proceeds to Bellicum from the offering are expected to be approximately $25.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Bellicum, excluding any proceeds that may be received upon exercise of the common warrants. Bellicum anticipates using the net proceeds from the offering, together with its existing capital resources, to fund ongoing and planned BPX-601 and BPX-603 clinical trials, and for general corporate purposes, including research and development and to fund working capital.</p>\n<p>The common warrants will be immediately exercisable at an exercise price of $6.50 per share of common stock and will expire five years from the date of issuance. The shares of common stock or the pre-funded warrants, and the accompanying common warrants, can only be purchased together in the offering but will be issued separately and will be immediately separable upon issuance. The offering is expected to close on or about November 3, 2020, subject to satisfaction of customary closing conditions.</p>\n<p>The securities described above are being sold by Bellicum pursuant to a shelf registration statement filed by Bellicum with the Securities and Exchange Commission (SEC), which was declared effective on July 30, 2019. The securities will be sold only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Electronic copies of the prospectus supplement and accompanying base prospectus may be obtained, when available, by contacting H.C. Wainwright &amp; Co., LLC, by emailing placements@hcwco.com or by calling 646-975-6996, or by visiting the SEC’s website at http://www.sec.gov.</p>\n<p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>\n<p><strong>About Bellicum Pharmaceuticals</strong></p>\n<p>Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum’s GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms.</p>\n<p><strong>Forward-Looking Statements</strong></p>\n<p>This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Bellicum may, in some cases, use terms such as “potential,” “continue,” “designed,” “expects,” “plans,” “intends,” “may,” “will,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding the expected gross proceeds from the offering, the intended use of net proceeds from the offering, anticipated closing of the offering and investor participation in the offering. Various factors may cause differences between Bellicum’s expectations and actual results, including risks and uncertainties associated with market conditions, the satisfaction of customary closing conditions related to the offering and the impact of general market, economic, industry or political conditions in the United States or internationally. There can be no assurance that Bellicum will be able to complete the offering. Additional risks and uncertainties relating to the offering, Bellicum and its business can be found in Bellicum’s filings with the Securities and Exchange Commission, including without limitation Bellicum’s quarterly report on Form 10-Q for the six months ended June 30, 2020, annual report on Form 10-K for the year ended December 31, 2019. Any forward-looking statements that Bellicum makes in this press release speak only as of the date of this press release. Bellicum assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release, except as required by law.</p>\n<p>Source: Bellicum Pharmaceuticals</p>\n<p>Investors:<br/>Robert H. Uhl<br/>Managing Director<br/>Westwicke ICR<br/>858-356-5932<br/>Robert.uhl@westwicke.com</p>\n<br/>\n<img height=\"1\" src=\"https://ml.globenewswire.com/release/track/132a64a1-0cf9-4dca-87a6-14d260ba4118\" width=\"1\"/></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-10-30 05:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/bellicum-announces-25-0-million-211600259.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the pricing of...</p>\n\n<a href=\"https://finance.yahoo.com/news/bellicum-announces-25-0-million-211600259.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZzuL59OZ9byWHgUSQeB_Ig--~B/aD0zNDg7dz0xMjUwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/kExCNQbHXvQZdEyLr9J37A--~B/aD0zNDg7dz0xMjUwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/e064887394fc72948ed8d83920e27107","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/bellicum-announces-25-0-million-211600259.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2079414686","content_text":"HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the pricing of an underwritten offering priced at-the-market under Nasdaq rules of 4,149,378 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase up to 4,149,378 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with one warrant to purchase one share of common stock at a combined effective price of $6.025. The offering is expected to involve a limited number of healthcare-dedicated institutional investors, including significant participation from two of Bellicum’s existing healthcare-dedicated institutional investors.\nH.C. Wainwright & Co. is acting as sole book-running manager for the offering.\nThe gross proceeds to Bellicum from the offering are expected to be approximately $25.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Bellicum, excluding any proceeds that may be received upon exercise of the common warrants. Bellicum anticipates using the net proceeds from the offering, together with its existing capital resources, to fund ongoing and planned BPX-601 and BPX-603 clinical trials, and for general corporate purposes, including research and development and to fund working capital.\nThe common warrants will be immediately exercisable at an exercise price of $6.50 per share of common stock and will expire five years from the date of issuance. The shares of common stock or the pre-funded warrants, and the accompanying common warrants, can only be purchased together in the offering but will be issued separately and will be immediately separable upon issuance. The offering is expected to close on or about November 3, 2020, subject to satisfaction of customary closing conditions.\nThe securities described above are being sold by Bellicum pursuant to a shelf registration statement filed by Bellicum with the Securities and Exchange Commission (SEC), which was declared effective on July 30, 2019. The securities will be sold only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Electronic copies of the prospectus supplement and accompanying base prospectus may be obtained, when available, by contacting H.C. Wainwright & Co., LLC, by emailing placements@hcwco.com or by calling 646-975-6996, or by visiting the SEC’s website at http://www.sec.gov.\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.\nAbout Bellicum Pharmaceuticals\nBellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum’s GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms.\nForward-Looking Statements\nThis press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Bellicum may, in some cases, use terms such as “potential,” “continue,” “designed,” “expects,” “plans,” “intends,” “may,” “will,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding the expected gross proceeds from the offering, the intended use of net proceeds from the offering, anticipated closing of the offering and investor participation in the offering. Various factors may cause differences between Bellicum’s expectations and actual results, including risks and uncertainties associated with market conditions, the satisfaction of customary closing conditions related to the offering and the impact of general market, economic, industry or political conditions in the United States or internationally. There can be no assurance that Bellicum will be able to complete the offering. Additional risks and uncertainties relating to the offering, Bellicum and its business can be found in Bellicum’s filings with the Securities and Exchange Commission, including without limitation Bellicum’s quarterly report on Form 10-Q for the six months ended June 30, 2020, annual report on Form 10-K for the year ended December 31, 2019. Any forward-looking statements that Bellicum makes in this press release speak only as of the date of this press release. Bellicum assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release, except as required by law.\nSource: Bellicum Pharmaceuticals\nInvestors:Robert H. UhlManaging DirectorWestwicke ICR858-356-5932Robert.uhl@westwicke.com","news_type":1},"isVote":1,"tweetType":1,"viewCount":2178,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":308471302,"gmtCreate":1604062610606,"gmtModify":1703831894961,"author":{"id":"3519516576436036","authorId":"3519516576436036","name":"民国卫士财神","avatar":"https://static.tigerbbs.com/d777c08923786c9a2d938a63d5edd6e1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3519516576436036","authorIdStr":"3519516576436036"},"themes":[],"htmlText":"增发股票了吗？","listText":"增发股票了吗？","text":"增发股票了吗？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/308471302","repostId":"2079414686","repostType":2,"repost":{"id":"2079414686","kind":"news","pubTimestamp":1604006160,"share":"https://www.laohu8.com/m/news/2079414686?lang=&edition=full","pubTime":"2020-10-30 05:16","market":"us","language":"en","title":"Bellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2079414686","media":"GlobeNewswire","summary":"HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in","content":"<html><body><p>HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/BLCM\">Bellicum Pharmaceuticals, Inc.</a> (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the pricing of an underwritten offering priced at-the-market under Nasdaq rules of 4,149,378 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase up to 4,149,378 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with <a href=\"https://laohu8.com/S/AONE\">one</a> warrant to purchase <a href=\"https://laohu8.com/S/AONE.U\">one</a> share of common stock at a combined effective price of $6.025. The offering is expected to involve a limited number of healthcare-dedicated institutional investors, including significant participation from two of Bellicum’s existing healthcare-dedicated institutional investors.<br/></p>\n<p>H.C. Wainwright &amp; Co. is acting as sole book-running manager for the offering.</p>\n<p>The gross proceeds to Bellicum from the offering are expected to be approximately $25.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Bellicum, excluding any proceeds that may be received upon exercise of the common warrants. Bellicum anticipates using the net proceeds from the offering, together with its existing capital resources, to fund ongoing and planned BPX-601 and BPX-603 clinical trials, and for general corporate purposes, including research and development and to fund working capital.</p>\n<p>The common warrants will be immediately exercisable at an exercise price of $6.50 per share of common stock and will expire five years from the date of issuance. The shares of common stock or the pre-funded warrants, and the accompanying common warrants, can only be purchased together in the offering but will be issued separately and will be immediately separable upon issuance. The offering is expected to close on or about November 3, 2020, subject to satisfaction of customary closing conditions.</p>\n<p>The securities described above are being sold by Bellicum pursuant to a shelf registration statement filed by Bellicum with the Securities and Exchange Commission (SEC), which was declared effective on July 30, 2019. The securities will be sold only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Electronic copies of the prospectus supplement and accompanying base prospectus may be obtained, when available, by contacting H.C. Wainwright &amp; Co., LLC, by emailing placements@hcwco.com or by calling 646-975-6996, or by visiting the SEC’s website at http://www.sec.gov.</p>\n<p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>\n<p><strong>About Bellicum Pharmaceuticals</strong></p>\n<p>Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum’s GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms.</p>\n<p><strong>Forward-Looking Statements</strong></p>\n<p>This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Bellicum may, in some cases, use terms such as “potential,” “continue,” “designed,” “expects,” “plans,” “intends,” “may,” “will,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding the expected gross proceeds from the offering, the intended use of net proceeds from the offering, anticipated closing of the offering and investor participation in the offering. Various factors may cause differences between Bellicum’s expectations and actual results, including risks and uncertainties associated with market conditions, the satisfaction of customary closing conditions related to the offering and the impact of general market, economic, industry or political conditions in the United States or internationally. There can be no assurance that Bellicum will be able to complete the offering. Additional risks and uncertainties relating to the offering, Bellicum and its business can be found in Bellicum’s filings with the Securities and Exchange Commission, including without limitation Bellicum’s quarterly report on Form 10-Q for the six months ended June 30, 2020, annual report on Form 10-K for the year ended December 31, 2019. Any forward-looking statements that Bellicum makes in this press release speak only as of the date of this press release. Bellicum assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release, except as required by law.</p>\n<p>Source: Bellicum Pharmaceuticals</p>\n<p>Investors:<br/>Robert H. Uhl<br/>Managing Director<br/>Westwicke ICR<br/>858-356-5932<br/>Robert.uhl@westwicke.com</p>\n<br/>\n<img height=\"1\" src=\"https://ml.globenewswire.com/release/track/132a64a1-0cf9-4dca-87a6-14d260ba4118\" width=\"1\"/></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-10-30 05:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/bellicum-announces-25-0-million-211600259.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the pricing of...</p>\n\n<a href=\"https://finance.yahoo.com/news/bellicum-announces-25-0-million-211600259.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZzuL59OZ9byWHgUSQeB_Ig--~B/aD0zNDg7dz0xMjUwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/kExCNQbHXvQZdEyLr9J37A--~B/aD0zNDg7dz0xMjUwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/e064887394fc72948ed8d83920e27107","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/bellicum-announces-25-0-million-211600259.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2079414686","content_text":"HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the pricing of an underwritten offering priced at-the-market under Nasdaq rules of 4,149,378 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase up to 4,149,378 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with one warrant to purchase one share of common stock at a combined effective price of $6.025. The offering is expected to involve a limited number of healthcare-dedicated institutional investors, including significant participation from two of Bellicum’s existing healthcare-dedicated institutional investors.\nH.C. Wainwright & Co. is acting as sole book-running manager for the offering.\nThe gross proceeds to Bellicum from the offering are expected to be approximately $25.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Bellicum, excluding any proceeds that may be received upon exercise of the common warrants. Bellicum anticipates using the net proceeds from the offering, together with its existing capital resources, to fund ongoing and planned BPX-601 and BPX-603 clinical trials, and for general corporate purposes, including research and development and to fund working capital.\nThe common warrants will be immediately exercisable at an exercise price of $6.50 per share of common stock and will expire five years from the date of issuance. The shares of common stock or the pre-funded warrants, and the accompanying common warrants, can only be purchased together in the offering but will be issued separately and will be immediately separable upon issuance. The offering is expected to close on or about November 3, 2020, subject to satisfaction of customary closing conditions.\nThe securities described above are being sold by Bellicum pursuant to a shelf registration statement filed by Bellicum with the Securities and Exchange Commission (SEC), which was declared effective on July 30, 2019. The securities will be sold only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Electronic copies of the prospectus supplement and accompanying base prospectus may be obtained, when available, by contacting H.C. Wainwright & Co., LLC, by emailing placements@hcwco.com or by calling 646-975-6996, or by visiting the SEC’s website at http://www.sec.gov.\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.\nAbout Bellicum Pharmaceuticals\nBellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum’s GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms.\nForward-Looking Statements\nThis press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Bellicum may, in some cases, use terms such as “potential,” “continue,” “designed,” “expects,” “plans,” “intends,” “may,” “will,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding the expected gross proceeds from the offering, the intended use of net proceeds from the offering, anticipated closing of the offering and investor participation in the offering. Various factors may cause differences between Bellicum’s expectations and actual results, including risks and uncertainties associated with market conditions, the satisfaction of customary closing conditions related to the offering and the impact of general market, economic, industry or political conditions in the United States or internationally. There can be no assurance that Bellicum will be able to complete the offering. Additional risks and uncertainties relating to the offering, Bellicum and its business can be found in Bellicum’s filings with the Securities and Exchange Commission, including without limitation Bellicum’s quarterly report on Form 10-Q for the six months ended June 30, 2020, annual report on Form 10-K for the year ended December 31, 2019. Any forward-looking statements that Bellicum makes in this press release speak only as of the date of this press release. Bellicum assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release, except as required by law.\nSource: Bellicum Pharmaceuticals\nInvestors:Robert H. UhlManaging DirectorWestwicke ICR858-356-5932Robert.uhl@westwicke.com","news_type":1},"isVote":1,"tweetType":1,"viewCount":1851,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":923548109,"gmtCreate":1585894712301,"gmtModify":1704359580864,"author":{"id":"3519516576436036","authorId":"3519516576436036","name":"民国卫士财神","avatar":"https://static.tigerbbs.com/d777c08923786c9a2d938a63d5edd6e1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3519516576436036","authorIdStr":"3519516576436036"},"themes":[],"htmlText":"呵呵，有神马用","listText":"呵呵，有神马用","text":"呵呵，有神马用","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/923548109","repostId":"1147107449","repostType":4,"isVote":1,"tweetType":1,"viewCount":1956,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":989507906,"gmtCreate":1582863482205,"gmtModify":1704348053770,"author":{"id":"3519516576436036","authorId":"3519516576436036","name":"民国卫士财神","avatar":"https://static.tigerbbs.com/d777c08923786c9a2d938a63d5edd6e1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3519516576436036","authorIdStr":"3519516576436036"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PTLA\">$Portola Pharmaceuticals Inc.(PTLA)$</a>先买个底仓，后面再加；","listText":"<a href=\"https://laohu8.com/S/PTLA\">$Portola Pharmaceuticals Inc.(PTLA)$</a>先买个底仓，后面再加；","text":"$Portola Pharmaceuticals Inc.(PTLA)$先买个底仓，后面再加；","images":[{"img":"https://static.tigerbbs.com/94df09bbfed66d8e85ac580c9b782e64","width":"750","height":"1068"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/989507906","isVote":1,"tweetType":1,"viewCount":3733,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":989507005,"gmtCreate":1582863418107,"gmtModify":1704348053597,"author":{"id":"3519516576436036","authorId":"3519516576436036","name":"民国卫士财神","avatar":"https://static.tigerbbs.com/d777c08923786c9a2d938a63d5edd6e1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3519516576436036","authorIdStr":"3519516576436036"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PTLA\">$Portola Pharmaceuticals Inc.(PTLA)$</a>买入1000股底仓，后面再加，准备放个几年","listText":"<a href=\"https://laohu8.com/S/PTLA\">$Portola Pharmaceuticals Inc.(PTLA)$</a>买入1000股底仓，后面再加，准备放个几年","text":"$Portola Pharmaceuticals Inc.(PTLA)$买入1000股底仓，后面再加，准备放个几年","images":[{"img":"https://static.tigerbbs.com/94df09bbfed66d8e85ac580c9b782e64","width":"750","height":"1068"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/989507005","isVote":1,"tweetType":1,"viewCount":3049,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":989504104,"gmtCreate":1582863301608,"gmtModify":1704348053079,"author":{"id":"3519516576436036","authorId":"3519516576436036","name":"民国卫士财神","avatar":"https://static.tigerbbs.com/d777c08923786c9a2d938a63d5edd6e1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3519516576436036","authorIdStr":"3519516576436036"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PTLA\">$Portola Pharmaceuticals Inc.(PTLA)$</a>我来建个仓，产品非常好；市场空间巨大，现在公司管理和销售出了问题。","listText":"<a href=\"https://laohu8.com/S/PTLA\">$Portola Pharmaceuticals Inc.(PTLA)$</a>我来建个仓，产品非常好；市场空间巨大，现在公司管理和销售出了问题。","text":"$Portola Pharmaceuticals Inc.(PTLA)$我来建个仓，产品非常好；市场空间巨大，现在公司管理和销售出了问题。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/989504104","isVote":1,"tweetType":1,"viewCount":2789,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":989505906,"gmtCreate":1582862835305,"gmtModify":1704348051171,"author":{"id":"3519516576436036","authorId":"3519516576436036","name":"民国卫士财神","avatar":"https://static.tigerbbs.com/d777c08923786c9a2d938a63d5edd6e1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3519516576436036","authorIdStr":"3519516576436036"},"themes":[],"htmlText":"厉害","listText":"厉害","text":"厉害","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/989505906","repostId":"1169038979","repostType":4,"isVote":1,"tweetType":1,"viewCount":1605,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667803686145","authorId":"3527667803686145","name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","crmLevel":1,"crmLevelSwitch":0,"idStr":"3527667803686145","authorIdStr":"3527667803686145"},"content":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题，可以获得更多曝光哦～如果您想创作优质文章，请查看老虎社区创作指引","text":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题，可以获得更多曝光哦～如果您想创作优质文章，请查看老虎社区创作指引","html":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题，可以获得更多曝光哦～如果您想创作优质文章，请查看老虎社区创作指引"}],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":989507906,"gmtCreate":1582863482205,"gmtModify":1704348053770,"author":{"id":"3519516576436036","authorId":"3519516576436036","name":"民国卫士财神","avatar":"https://static.tigerbbs.com/d777c08923786c9a2d938a63d5edd6e1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3519516576436036","authorIdStr":"3519516576436036"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PTLA\">$Portola Pharmaceuticals Inc.(PTLA)$</a>先买个底仓，后面再加；","listText":"<a href=\"https://laohu8.com/S/PTLA\">$Portola Pharmaceuticals Inc.(PTLA)$</a>先买个底仓，后面再加；","text":"$Portola Pharmaceuticals Inc.(PTLA)$先买个底仓，后面再加；","images":[{"img":"https://static.tigerbbs.com/94df09bbfed66d8e85ac580c9b782e64","width":"750","height":"1068"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/989507906","isVote":1,"tweetType":1,"viewCount":3733,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":989507005,"gmtCreate":1582863418107,"gmtModify":1704348053597,"author":{"id":"3519516576436036","authorId":"3519516576436036","name":"民国卫士财神","avatar":"https://static.tigerbbs.com/d777c08923786c9a2d938a63d5edd6e1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3519516576436036","authorIdStr":"3519516576436036"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PTLA\">$Portola Pharmaceuticals Inc.(PTLA)$</a>买入1000股底仓，后面再加，准备放个几年","listText":"<a href=\"https://laohu8.com/S/PTLA\">$Portola Pharmaceuticals Inc.(PTLA)$</a>买入1000股底仓，后面再加，准备放个几年","text":"$Portola Pharmaceuticals Inc.(PTLA)$买入1000股底仓，后面再加，准备放个几年","images":[{"img":"https://static.tigerbbs.com/94df09bbfed66d8e85ac580c9b782e64","width":"750","height":"1068"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/989507005","isVote":1,"tweetType":1,"viewCount":3049,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":989505906,"gmtCreate":1582862835305,"gmtModify":1704348051171,"author":{"id":"3519516576436036","authorId":"3519516576436036","name":"民国卫士财神","avatar":"https://static.tigerbbs.com/d777c08923786c9a2d938a63d5edd6e1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3519516576436036","authorIdStr":"3519516576436036"},"themes":[],"htmlText":"厉害","listText":"厉害","text":"厉害","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/989505906","repostId":"1169038979","repostType":4,"isVote":1,"tweetType":1,"viewCount":1605,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667803686145","authorId":"3527667803686145","name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","crmLevel":1,"crmLevelSwitch":0,"idStr":"3527667803686145","authorIdStr":"3527667803686145"},"content":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题，可以获得更多曝光哦～如果您想创作优质文章，请查看老虎社区创作指引","text":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题，可以获得更多曝光哦～如果您想创作优质文章，请查看老虎社区创作指引","html":"终于等到了您的初发帖[比心][比心]发帖时关联相关股票或者相关话题，可以获得更多曝光哦～如果您想创作优质文章，请查看老虎社区创作指引"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":308471888,"gmtCreate":1604062629544,"gmtModify":1703831895477,"author":{"id":"3519516576436036","authorId":"3519516576436036","name":"民国卫士财神","avatar":"https://static.tigerbbs.com/d777c08923786c9a2d938a63d5edd6e1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3519516576436036","authorIdStr":"3519516576436036"},"themes":[],"htmlText":"好像是400多万股","listText":"好像是400多万股","text":"好像是400多万股","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/308471888","repostId":"2079414686","repostType":2,"repost":{"id":"2079414686","kind":"news","pubTimestamp":1604006160,"share":"https://www.laohu8.com/m/news/2079414686?lang=&edition=full","pubTime":"2020-10-30 05:16","market":"us","language":"en","title":"Bellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2079414686","media":"GlobeNewswire","summary":"HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in","content":"<html><body><p>HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/BLCM\">Bellicum Pharmaceuticals, Inc.</a> (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the pricing of an underwritten offering priced at-the-market under Nasdaq rules of 4,149,378 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase up to 4,149,378 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with <a href=\"https://laohu8.com/S/AONE\">one</a> warrant to purchase <a href=\"https://laohu8.com/S/AONE.U\">one</a> share of common stock at a combined effective price of $6.025. The offering is expected to involve a limited number of healthcare-dedicated institutional investors, including significant participation from two of Bellicum’s existing healthcare-dedicated institutional investors.<br/></p>\n<p>H.C. Wainwright &amp; Co. is acting as sole book-running manager for the offering.</p>\n<p>The gross proceeds to Bellicum from the offering are expected to be approximately $25.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Bellicum, excluding any proceeds that may be received upon exercise of the common warrants. Bellicum anticipates using the net proceeds from the offering, together with its existing capital resources, to fund ongoing and planned BPX-601 and BPX-603 clinical trials, and for general corporate purposes, including research and development and to fund working capital.</p>\n<p>The common warrants will be immediately exercisable at an exercise price of $6.50 per share of common stock and will expire five years from the date of issuance. The shares of common stock or the pre-funded warrants, and the accompanying common warrants, can only be purchased together in the offering but will be issued separately and will be immediately separable upon issuance. The offering is expected to close on or about November 3, 2020, subject to satisfaction of customary closing conditions.</p>\n<p>The securities described above are being sold by Bellicum pursuant to a shelf registration statement filed by Bellicum with the Securities and Exchange Commission (SEC), which was declared effective on July 30, 2019. The securities will be sold only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Electronic copies of the prospectus supplement and accompanying base prospectus may be obtained, when available, by contacting H.C. Wainwright &amp; Co., LLC, by emailing placements@hcwco.com or by calling 646-975-6996, or by visiting the SEC’s website at http://www.sec.gov.</p>\n<p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>\n<p><strong>About Bellicum Pharmaceuticals</strong></p>\n<p>Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum’s GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms.</p>\n<p><strong>Forward-Looking Statements</strong></p>\n<p>This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Bellicum may, in some cases, use terms such as “potential,” “continue,” “designed,” “expects,” “plans,” “intends,” “may,” “will,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding the expected gross proceeds from the offering, the intended use of net proceeds from the offering, anticipated closing of the offering and investor participation in the offering. Various factors may cause differences between Bellicum’s expectations and actual results, including risks and uncertainties associated with market conditions, the satisfaction of customary closing conditions related to the offering and the impact of general market, economic, industry or political conditions in the United States or internationally. There can be no assurance that Bellicum will be able to complete the offering. Additional risks and uncertainties relating to the offering, Bellicum and its business can be found in Bellicum’s filings with the Securities and Exchange Commission, including without limitation Bellicum’s quarterly report on Form 10-Q for the six months ended June 30, 2020, annual report on Form 10-K for the year ended December 31, 2019. Any forward-looking statements that Bellicum makes in this press release speak only as of the date of this press release. Bellicum assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release, except as required by law.</p>\n<p>Source: Bellicum Pharmaceuticals</p>\n<p>Investors:<br/>Robert H. Uhl<br/>Managing Director<br/>Westwicke ICR<br/>858-356-5932<br/>Robert.uhl@westwicke.com</p>\n<br/>\n<img height=\"1\" src=\"https://ml.globenewswire.com/release/track/132a64a1-0cf9-4dca-87a6-14d260ba4118\" width=\"1\"/></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-10-30 05:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/bellicum-announces-25-0-million-211600259.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the pricing of...</p>\n\n<a href=\"https://finance.yahoo.com/news/bellicum-announces-25-0-million-211600259.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZzuL59OZ9byWHgUSQeB_Ig--~B/aD0zNDg7dz0xMjUwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/kExCNQbHXvQZdEyLr9J37A--~B/aD0zNDg7dz0xMjUwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/e064887394fc72948ed8d83920e27107","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/bellicum-announces-25-0-million-211600259.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2079414686","content_text":"HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the pricing of an underwritten offering priced at-the-market under Nasdaq rules of 4,149,378 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase up to 4,149,378 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with one warrant to purchase one share of common stock at a combined effective price of $6.025. The offering is expected to involve a limited number of healthcare-dedicated institutional investors, including significant participation from two of Bellicum’s existing healthcare-dedicated institutional investors.\nH.C. Wainwright & Co. is acting as sole book-running manager for the offering.\nThe gross proceeds to Bellicum from the offering are expected to be approximately $25.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Bellicum, excluding any proceeds that may be received upon exercise of the common warrants. Bellicum anticipates using the net proceeds from the offering, together with its existing capital resources, to fund ongoing and planned BPX-601 and BPX-603 clinical trials, and for general corporate purposes, including research and development and to fund working capital.\nThe common warrants will be immediately exercisable at an exercise price of $6.50 per share of common stock and will expire five years from the date of issuance. The shares of common stock or the pre-funded warrants, and the accompanying common warrants, can only be purchased together in the offering but will be issued separately and will be immediately separable upon issuance. The offering is expected to close on or about November 3, 2020, subject to satisfaction of customary closing conditions.\nThe securities described above are being sold by Bellicum pursuant to a shelf registration statement filed by Bellicum with the Securities and Exchange Commission (SEC), which was declared effective on July 30, 2019. The securities will be sold only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Electronic copies of the prospectus supplement and accompanying base prospectus may be obtained, when available, by contacting H.C. Wainwright & Co., LLC, by emailing placements@hcwco.com or by calling 646-975-6996, or by visiting the SEC’s website at http://www.sec.gov.\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.\nAbout Bellicum Pharmaceuticals\nBellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum’s GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms.\nForward-Looking Statements\nThis press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Bellicum may, in some cases, use terms such as “potential,” “continue,” “designed,” “expects,” “plans,” “intends,” “may,” “will,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding the expected gross proceeds from the offering, the intended use of net proceeds from the offering, anticipated closing of the offering and investor participation in the offering. Various factors may cause differences between Bellicum’s expectations and actual results, including risks and uncertainties associated with market conditions, the satisfaction of customary closing conditions related to the offering and the impact of general market, economic, industry or political conditions in the United States or internationally. There can be no assurance that Bellicum will be able to complete the offering. Additional risks and uncertainties relating to the offering, Bellicum and its business can be found in Bellicum’s filings with the Securities and Exchange Commission, including without limitation Bellicum’s quarterly report on Form 10-Q for the six months ended June 30, 2020, annual report on Form 10-K for the year ended December 31, 2019. Any forward-looking statements that Bellicum makes in this press release speak only as of the date of this press release. Bellicum assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release, except as required by law.\nSource: Bellicum Pharmaceuticals\nInvestors:Robert H. UhlManaging DirectorWestwicke ICR858-356-5932Robert.uhl@westwicke.com","news_type":1},"isVote":1,"tweetType":1,"viewCount":2178,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":385554793,"gmtCreate":1613567195512,"gmtModify":1613567195512,"author":{"id":"3519516576436036","authorId":"3519516576436036","name":"民国卫士财神","avatar":"https://static.tigerbbs.com/d777c08923786c9a2d938a63d5edd6e1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3519516576436036","authorIdStr":"3519516576436036"},"themes":[],"htmlText":"就是割韭菜的忽悠，估计公司正准备增发股票割韭菜泡汤了","listText":"就是割韭菜的忽悠，估计公司正准备增发股票割韭菜泡汤了","text":"就是割韭菜的忽悠，估计公司正准备增发股票割韭菜泡汤了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/385554793","repostId":"2112710837","repostType":2,"repost":{"id":"2112710837","kind":"news","pubTimestamp":1613565105,"share":"https://www.laohu8.com/m/news/2112710837?lang=&edition=full","pubTime":"2021-02-17 20:31","market":"hk","language":"zh","title":"美股异动 | 亿航智能(EH.US)盘前转跌逾15% 成交额已超1亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2112710837","media":"智通财经","summary":"智通财经APP获悉，亿航智能(EH.US)盘前交投活跃，股价涨超34%后转跌逾15%，成交额已超1亿。截止发稿，跌9.05%，报42.11美元，成交额1.03亿美元。消息面上，针对Wolfpack  Research于2021年2月16日发布的一份报告中提出的指控，亿航智能发布声明称，公司坚信报告中包含大量错误、未经证实的陈述和对信息的误读。公司将考虑采取任何必要和适当的行动来保护公司及其所有股东的利益。亿航智能致力于保持最高标准的公司治理，并按照美国证券交易委员会和纳斯达克股票市场的适用规则和法规进行透明和及时的披露。","content":"<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/EH\">亿航智能</a>(EH.US)盘前交投活跃，股价涨超34%后转跌逾15%，成交额已超1亿。截止发稿，跌9.05%，报42.11美元，成交额1.03亿美元。</p><p>消息面上，针对Wolfpack  Research于2021年2月16日发布的一份报告中提出的指控，亿航智能发布声明称，公司坚信报告中包含大量错误、未经证实的陈述和对信息的误读。公司将考虑采取任何必要和适当的行动来保护公司及其所有股东的利益。亿航智能致力于保持最高标准的公司治理，并按照美国证券交易委员会和纳斯达克股票市场的适用规则和法规进行透明和及时的披露。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美股异动 | 亿航智能(EH.US)盘前转跌逾15% 成交额已超1亿</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美股异动 | 亿航智能(EH.US)盘前转跌逾15% 成交额已超1亿\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-17 20:31 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/412490.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，亿航智能(EH.US)盘前交投活跃，股价涨超34%后转跌逾15%，成交额已超1亿。截止发稿，跌9.05%，报42.11美元，成交额1.03亿美元。消息面上，针对Wolfpack  Research于2021年2月16日发布的一份报告中提出的指控，亿航智能发布声明称，公司坚信报告中包含大量错误、未经证实的陈述和对信息的误读。公司将考虑采取任何必要和适当的行动来保护公司及其所有股东...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/412490.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750","relate_stocks":{"EH":"亿航智能"},"source_url":"http://www.zhitongcaijing.com/content/detail/412490.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2112710837","content_text":"智通财经APP获悉，亿航智能(EH.US)盘前交投活跃，股价涨超34%后转跌逾15%，成交额已超1亿。截止发稿，跌9.05%，报42.11美元，成交额1.03亿美元。消息面上，针对Wolfpack  Research于2021年2月16日发布的一份报告中提出的指控，亿航智能发布声明称，公司坚信报告中包含大量错误、未经证实的陈述和对信息的误读。公司将考虑采取任何必要和适当的行动来保护公司及其所有股东的利益。亿航智能致力于保持最高标准的公司治理，并按照美国证券交易委员会和纳斯达克股票市场的适用规则和法规进行透明和及时的披露。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1487,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":380748026,"gmtCreate":1612602193265,"gmtModify":1703763950438,"author":{"id":"3519516576436036","authorId":"3519516576436036","name":"民国卫士财神","avatar":"https://static.tigerbbs.com/d777c08923786c9a2d938a63d5edd6e1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3519516576436036","authorIdStr":"3519516576436036"},"themes":[],"htmlText":"管理层吃老本，要不了多久就被被淘汰掉，看吧","listText":"管理层吃老本，要不了多久就被被淘汰掉，看吧","text":"管理层吃老本，要不了多久就被被淘汰掉，看吧","images":[{"img":"https://static.tigerbbs.com/b0e3ec13953a98a2a7ad61c45ec8f2ee","width":"1176","height":"2860"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/380748026","isVote":1,"tweetType":1,"viewCount":2902,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":380741601,"gmtCreate":1612602043103,"gmtModify":1703763949920,"author":{"id":"3519516576436036","authorId":"3519516576436036","name":"民国卫士财神","avatar":"https://static.tigerbbs.com/d777c08923786c9a2d938a63d5edd6e1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3519516576436036","authorIdStr":"3519516576436036"},"themes":[],"htmlText":"一个10年350倍回报的公司，太励志了，保存一下","listText":"一个10年350倍回报的公司，太励志了，保存一下","text":"一个10年350倍回报的公司，太励志了，保存一下","images":[{"img":"https://static.tigerbbs.com/17f1154c260ba3beffd6d70db6e71c7c","width":"1176","height":"2959"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/380741601","isVote":1,"tweetType":1,"viewCount":3278,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":380304195,"gmtCreate":1612512034017,"gmtModify":1703762892228,"author":{"id":"3519516576436036","authorId":"3519516576436036","name":"民国卫士财神","avatar":"https://static.tigerbbs.com/d777c08923786c9a2d938a63d5edd6e1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3519516576436036","authorIdStr":"3519516576436036"},"themes":[],"htmlText":"好讨厌的一个品牌，到处刷存在，核心技术全部拿来主义，一个不专注品质的公司，是不值得投资的","listText":"好讨厌的一个品牌，到处刷存在，核心技术全部拿来主义，一个不专注品质的公司，是不值得投资的","text":"好讨厌的一个品牌，到处刷存在，核心技术全部拿来主义，一个不专注品质的公司，是不值得投资的","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/380304195","repostId":"2109729194","repostType":2,"repost":{"id":"2109729194","kind":"news","pubTimestamp":1612509420,"share":"https://www.laohu8.com/m/news/2109729194?lang=&edition=full","pubTime":"2021-02-05 15:17","market":"hk","language":"zh","title":"小米发布四曲瀑布屏概念机，四周边框全部消失","url":"https://stock-news.laohu8.com/highlight/detail?id=2109729194","media":"界面新闻","summary":"同时，小米四曲瀑布屏概念机采用了无孔设计，目前手机已有的实体按键与所有开孔全部消失，充电方式为大功率无线充电。小米四曲瀑布屏概念机取消了实体键，那么如何解决音量键也是这款产品的看点之一。值得一提的是，2019年9月，小米曾发布过MIX Alpha环绕屏概念手机，但由于工艺难题最终放弃量产。因此，目前小米四曲瀑布屏概念机并未公布售价，也未宣布是否会正式量产。","content":"<div>\n<p>记者｜王公逸2月5日，小米四曲瀑布屏概念机正式亮相。此款概念机四面为88°超曲边框，从官方释出的视频以及图片中基本可知，从正面观看很难看到手机的四面边框，实现了真正的“视觉无边框”。同时，小米四曲瀑布屏概念机采用了无孔设计，目前手机已有的实体按键与所有开孔全部消失，充电方式为大功率无线充电。同时为了保留前置镜头，新机应该会采用屏下摄像头的方案。此外，该款产品也通过柔性薄膜屏幕发声技术，以此来替代...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202102051518017a47c40f&s=b\">Web Link</a>\n\n</div>\n","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>小米发布四曲瀑布屏概念机，四周边框全部消失</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n小米发布四曲瀑布屏概念机，四周边框全部消失\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-05 15:17 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202102051518017a47c40f&s=b><strong>界面新闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>记者｜王公逸2月5日，小米四曲瀑布屏概念机正式亮相。此款概念机四面为88°超曲边框，从官方释出的视频以及图片中基本可知，从正面观看很难看到手机的四面边框，实现了真正的“视觉无边框”。同时，小米四曲瀑布屏概念机采用了无孔设计，目前手机已有的实体按键与所有开孔全部消失，充电方式为大功率无线充电。同时为了保留前置镜头，新机应该会采用屏下摄像头的方案。此外，该款产品也通过柔性薄膜屏幕发声技术，以此来替代...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202102051518017a47c40f&s=b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/3df686d3a6ca977e8c6841905eb7e18c","relate_stocks":{"01810":"小米集团-W"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202102051518017a47c40f&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2109729194","content_text":"记者｜王公逸2月5日，小米四曲瀑布屏概念机正式亮相。此款概念机四面为88°超曲边框，从官方释出的视频以及图片中基本可知，从正面观看很难看到手机的四面边框，实现了真正的“视觉无边框”。同时，小米四曲瀑布屏概念机采用了无孔设计，目前手机已有的实体按键与所有开孔全部消失，充电方式为大功率无线充电。同时为了保留前置镜头，新机应该会采用屏下摄像头的方案。此外，该款产品也通过柔性薄膜屏幕发声技术，以此来替代智能手机上的传统听筒。小米四曲瀑布屏概念机取消了实体键，那么如何解决音量键也是这款产品的看点之一。此前，作为替代音量键的方案，华为曾采用了双敲侧边呼出的设计，而vivo也推出过压感振动的解决方案。雷军此前曾在微博透露，小米未来可能发布一款万元高端手机，外界猜测可能是小米的折叠屏新机，但目前来看，也可能会是这款四曲瀑布屏概念机。值得一提的是，2019年9月，小米曾发布过MIX Alpha环绕屏概念手机，但由于工艺难题最终放弃量产。因此，目前小米四曲瀑布屏概念机并未公布售价，也未宣布是否会正式量产。","news_type":1},"isVote":1,"tweetType":1,"viewCount":2697,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":308471302,"gmtCreate":1604062610606,"gmtModify":1703831894961,"author":{"id":"3519516576436036","authorId":"3519516576436036","name":"民国卫士财神","avatar":"https://static.tigerbbs.com/d777c08923786c9a2d938a63d5edd6e1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3519516576436036","authorIdStr":"3519516576436036"},"themes":[],"htmlText":"增发股票了吗？","listText":"增发股票了吗？","text":"增发股票了吗？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/308471302","repostId":"2079414686","repostType":2,"repost":{"id":"2079414686","kind":"news","pubTimestamp":1604006160,"share":"https://www.laohu8.com/m/news/2079414686?lang=&edition=full","pubTime":"2020-10-30 05:16","market":"us","language":"en","title":"Bellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2079414686","media":"GlobeNewswire","summary":"HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in","content":"<html><body><p>HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/BLCM\">Bellicum Pharmaceuticals, Inc.</a> (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the pricing of an underwritten offering priced at-the-market under Nasdaq rules of 4,149,378 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase up to 4,149,378 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with <a href=\"https://laohu8.com/S/AONE\">one</a> warrant to purchase <a href=\"https://laohu8.com/S/AONE.U\">one</a> share of common stock at a combined effective price of $6.025. The offering is expected to involve a limited number of healthcare-dedicated institutional investors, including significant participation from two of Bellicum’s existing healthcare-dedicated institutional investors.<br/></p>\n<p>H.C. Wainwright &amp; Co. is acting as sole book-running manager for the offering.</p>\n<p>The gross proceeds to Bellicum from the offering are expected to be approximately $25.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Bellicum, excluding any proceeds that may be received upon exercise of the common warrants. Bellicum anticipates using the net proceeds from the offering, together with its existing capital resources, to fund ongoing and planned BPX-601 and BPX-603 clinical trials, and for general corporate purposes, including research and development and to fund working capital.</p>\n<p>The common warrants will be immediately exercisable at an exercise price of $6.50 per share of common stock and will expire five years from the date of issuance. The shares of common stock or the pre-funded warrants, and the accompanying common warrants, can only be purchased together in the offering but will be issued separately and will be immediately separable upon issuance. The offering is expected to close on or about November 3, 2020, subject to satisfaction of customary closing conditions.</p>\n<p>The securities described above are being sold by Bellicum pursuant to a shelf registration statement filed by Bellicum with the Securities and Exchange Commission (SEC), which was declared effective on July 30, 2019. The securities will be sold only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Electronic copies of the prospectus supplement and accompanying base prospectus may be obtained, when available, by contacting H.C. Wainwright &amp; Co., LLC, by emailing placements@hcwco.com or by calling 646-975-6996, or by visiting the SEC’s website at http://www.sec.gov.</p>\n<p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>\n<p><strong>About Bellicum Pharmaceuticals</strong></p>\n<p>Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum’s GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms.</p>\n<p><strong>Forward-Looking Statements</strong></p>\n<p>This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Bellicum may, in some cases, use terms such as “potential,” “continue,” “designed,” “expects,” “plans,” “intends,” “may,” “will,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding the expected gross proceeds from the offering, the intended use of net proceeds from the offering, anticipated closing of the offering and investor participation in the offering. Various factors may cause differences between Bellicum’s expectations and actual results, including risks and uncertainties associated with market conditions, the satisfaction of customary closing conditions related to the offering and the impact of general market, economic, industry or political conditions in the United States or internationally. There can be no assurance that Bellicum will be able to complete the offering. Additional risks and uncertainties relating to the offering, Bellicum and its business can be found in Bellicum’s filings with the Securities and Exchange Commission, including without limitation Bellicum’s quarterly report on Form 10-Q for the six months ended June 30, 2020, annual report on Form 10-K for the year ended December 31, 2019. Any forward-looking statements that Bellicum makes in this press release speak only as of the date of this press release. Bellicum assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release, except as required by law.</p>\n<p>Source: Bellicum Pharmaceuticals</p>\n<p>Investors:<br/>Robert H. Uhl<br/>Managing Director<br/>Westwicke ICR<br/>858-356-5932<br/>Robert.uhl@westwicke.com</p>\n<br/>\n<img height=\"1\" src=\"https://ml.globenewswire.com/release/track/132a64a1-0cf9-4dca-87a6-14d260ba4118\" width=\"1\"/></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-10-30 05:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/bellicum-announces-25-0-million-211600259.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the pricing of...</p>\n\n<a href=\"https://finance.yahoo.com/news/bellicum-announces-25-0-million-211600259.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZzuL59OZ9byWHgUSQeB_Ig--~B/aD0zNDg7dz0xMjUwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/kExCNQbHXvQZdEyLr9J37A--~B/aD0zNDg7dz0xMjUwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/e064887394fc72948ed8d83920e27107","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/bellicum-announces-25-0-million-211600259.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2079414686","content_text":"HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the pricing of an underwritten offering priced at-the-market under Nasdaq rules of 4,149,378 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase up to 4,149,378 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with one warrant to purchase one share of common stock at a combined effective price of $6.025. The offering is expected to involve a limited number of healthcare-dedicated institutional investors, including significant participation from two of Bellicum’s existing healthcare-dedicated institutional investors.\nH.C. Wainwright & Co. is acting as sole book-running manager for the offering.\nThe gross proceeds to Bellicum from the offering are expected to be approximately $25.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Bellicum, excluding any proceeds that may be received upon exercise of the common warrants. Bellicum anticipates using the net proceeds from the offering, together with its existing capital resources, to fund ongoing and planned BPX-601 and BPX-603 clinical trials, and for general corporate purposes, including research and development and to fund working capital.\nThe common warrants will be immediately exercisable at an exercise price of $6.50 per share of common stock and will expire five years from the date of issuance. The shares of common stock or the pre-funded warrants, and the accompanying common warrants, can only be purchased together in the offering but will be issued separately and will be immediately separable upon issuance. The offering is expected to close on or about November 3, 2020, subject to satisfaction of customary closing conditions.\nThe securities described above are being sold by Bellicum pursuant to a shelf registration statement filed by Bellicum with the Securities and Exchange Commission (SEC), which was declared effective on July 30, 2019. The securities will be sold only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Electronic copies of the prospectus supplement and accompanying base prospectus may be obtained, when available, by contacting H.C. Wainwright & Co., LLC, by emailing placements@hcwco.com or by calling 646-975-6996, or by visiting the SEC’s website at http://www.sec.gov.\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.\nAbout Bellicum Pharmaceuticals\nBellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum’s GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms.\nForward-Looking Statements\nThis press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Bellicum may, in some cases, use terms such as “potential,” “continue,” “designed,” “expects,” “plans,” “intends,” “may,” “will,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding the expected gross proceeds from the offering, the intended use of net proceeds from the offering, anticipated closing of the offering and investor participation in the offering. Various factors may cause differences between Bellicum’s expectations and actual results, including risks and uncertainties associated with market conditions, the satisfaction of customary closing conditions related to the offering and the impact of general market, economic, industry or political conditions in the United States or internationally. There can be no assurance that Bellicum will be able to complete the offering. Additional risks and uncertainties relating to the offering, Bellicum and its business can be found in Bellicum’s filings with the Securities and Exchange Commission, including without limitation Bellicum’s quarterly report on Form 10-Q for the six months ended June 30, 2020, annual report on Form 10-K for the year ended December 31, 2019. Any forward-looking statements that Bellicum makes in this press release speak only as of the date of this press release. Bellicum assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release, except as required by law.\nSource: Bellicum Pharmaceuticals\nInvestors:Robert H. UhlManaging DirectorWestwicke ICR858-356-5932Robert.uhl@westwicke.com","news_type":1},"isVote":1,"tweetType":1,"viewCount":1851,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":923548109,"gmtCreate":1585894712301,"gmtModify":1704359580864,"author":{"id":"3519516576436036","authorId":"3519516576436036","name":"民国卫士财神","avatar":"https://static.tigerbbs.com/d777c08923786c9a2d938a63d5edd6e1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3519516576436036","authorIdStr":"3519516576436036"},"themes":[],"htmlText":"呵呵，有神马用","listText":"呵呵，有神马用","text":"呵呵，有神马用","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/923548109","repostId":"1147107449","repostType":4,"isVote":1,"tweetType":1,"viewCount":1956,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":989504104,"gmtCreate":1582863301608,"gmtModify":1704348053079,"author":{"id":"3519516576436036","authorId":"3519516576436036","name":"民国卫士财神","avatar":"https://static.tigerbbs.com/d777c08923786c9a2d938a63d5edd6e1","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3519516576436036","authorIdStr":"3519516576436036"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/PTLA\">$Portola Pharmaceuticals Inc.(PTLA)$</a>我来建个仓，产品非常好；市场空间巨大，现在公司管理和销售出了问题。","listText":"<a href=\"https://laohu8.com/S/PTLA\">$Portola Pharmaceuticals Inc.(PTLA)$</a>我来建个仓，产品非常好；市场空间巨大，现在公司管理和销售出了问题。","text":"$Portola Pharmaceuticals Inc.(PTLA)$我来建个仓，产品非常好；市场空间巨大，现在公司管理和销售出了问题。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/989504104","isVote":1,"tweetType":1,"viewCount":2789,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}